A5103149145- Coagulation, Bradykinin, Polyphosphates, and Angioedema
- Apelin-related biomedical research
- Protein Degradation and Inhibitors
- Blood Coagulation and Thrombosis Mechanisms
- CAR-T cell therapy research
- Multiple Myeloma Research and Treatments
- Birth, Development, and Health
- Atherosclerosis and Cardiovascular Diseases
- Gestational Diabetes Research and Management
- Bacterial Infections and Vaccines
- Head and Neck Surgical Oncology
- Heart Rate Variability and Autonomic Control
- Adipokines, Inflammation, and Metabolic Diseases
- Spine and Intervertebral Disc Pathology
- Cardiovascular Issues in Pregnancy
- Peptidase Inhibition and Analysis
- Soft tissue tumor case studies
- Tumors and Oncological Cases
- Sarcoma Diagnosis and Treatment
- Protease and Inhibitor Mechanisms
- Ear and Head Tumors
- Cancer therapeutics and mechanisms
- Pregnancy and preeclampsia studies
- Streptococcal Infections and Treatments
- Nonmelanoma Skin Cancer Studies
Medical University of South Carolina
2023-2024
Bridgepoint (United Kingdom)
2013
Deutsches Herzzentrum der Charité
2009
To evaluate the potential contribution of maternal glucose and lipids to fetal metabolic variables growth in pregnancies with normal tolerance comparison well-controlled gestational diabetes previously reported by us.In 190 oral tests (controls), insulin, lipid components were determined arterial cord blood serum. Birthweight neonatal fat mass obtained after delivery. Values adjusted for pre-pregnancy BMI, Caesarean section age. Measurements compared those reported.Maternal serum glucose,...
The degradation of bradykinin by angiotensin-converting-enzyme (ACE) activity in cultured human endothelial cells was studied direct measurement and its effect on the release endothelium-derived relaxing factors. half-life exogenous (10,000 pg/ml) calculated from decay concentration as 46 +/- 2 min cell monolayers, 133 15 conditioned medium, 24 homogenates. Most bradykinin-degrading monolayers could be inhibited a concentration-dependent manner ACE inhibitors lisinopril, ramiprilat,...
Teclistamab is a B-cell maturation antigen (BCMA)-directed bispecific T-cell engager approved for relapsed-refractory multiple myeloma (RRMM). Cytokine release syndrome (CRS) and Immune effector cell-associated neurotoxicity (ICANS) are well-documented treatment -related adverse events of teclistamab. The prescribing information recommends step-up dosing on days 1, 4, 7 with 48-72 h inpatient observation after each dose to monitor CRS. This leads more than weeklong hospital stay, adding the...
Introduction: TP53 alterations are associated with poor prognosis in mantle cell lymphoma (MCL). In trials of intensive chemotherapy and autologous hematopoietic transplant (auto-HCT), patients (pts) mutations had an overall survival (OS) 1.8 years (yrs) compared to 12.7 yrs for unmutated. Optimal treatment achieve durable remission is unknown. We report cellular therapy outcomes a large cohort pts altered MCL. Methods: conducted multi-site retrospective study MCL harboring mutation,...
Hintergrund: Kinder von Müttern mit Gestationsdiabetes haben ein erhöhtes Risiko makrosom geboren zu werden. Die Langzeitauswirkungen der übermäßigen intrauterinen Gewichtszunahme auf die Entwicklung Übergewicht und Stoffwechselstörungen dieser ist wenig untersucht [1].